Trial site
Retina Consultants of Southern California
Redlands, California 92374, United StatesNot linked to an institution yet
- 7running trials
- 8closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 22 trials
- Phase 2/31 trial
- Status
- Completed8 trials
- Active, not recruiting5 trials
- Recruiting2 trials
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.3 trials
- Kodiak Sciences Inc3 trials
- Hoffmann-La Roche2 trials
- Astellas Pharma Global Development, Inc.1 trial
- Bayer1 trial
- and 5 more
Running trials
Active, not recruiting
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399· Phase 3· Kodiak Sciences Inc· Source
Contact: Kodiak Sciences Inc
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080· Phase 3· Kodiak Sciences Inc· Source
Contact: Kodiak Sciences Inc
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
NCT06491914· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916· Phase 2· Kyowa Kirin Co., Ltd.· Source
Report an error